{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=5", "query": { "intervention": "TDF/FTC", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 352, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T06:01:29.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01025427", "title": "HIV Persistence and Viral Reservoirs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Raltegravir, tenofovir/emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01025427" }, { "nct_id": "NCT00959894", "title": "Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Etravirine (Intelence)", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2009-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959894" }, { "nct_id": "NCT00724711", "title": "Safety and Efficacy Study of Switching From Epzicom to Truvada", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)", "type": "DRUG" }, { "name": "abacavir (ABC)/lamivudine (3TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2008-07", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 73, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00724711" }, { "nct_id": "NCT01641809", "title": "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1265744 10 mg", "type": "DRUG" }, { "name": "GSK1265744 30 mg", "type": "DRUG" }, { "name": "GSK1265744 60 mg", "type": "DRUG" }, { "name": "Efavirenz 600 mg", "type": "DRUG" }, { "name": "Rilpivirine 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-08-06", "completion_date": "2019-01-15", "has_results": true, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641809" }, { "nct_id": "NCT01440569", "title": "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2011-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440569" }, { "nct_id": "NCT04760691", "title": "Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV", "Prophylaxis", "Transgender" ], "interventions": [ { "name": "Truvada alone", "type": "DRUG" }, { "name": "Truvada plus Leuprolide 11.25mg intramuscular injection", "type": "DRUG" }, { "name": "Truvada plus Estradiol 1 mg", "type": "DRUG" }, { "name": "Truvada plus Estradiol 6 mg", "type": "DRUG" }, { "name": "Estradiol 6 mg alone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2021-03-01", "completion_date": "2025-03-24", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04760691" }, { "nct_id": "NCT00116805", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 266, "start_date": "2005-06", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 20, "location_summary": "Orange, California • Pasadena, California • San Diego, California + 14 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116805" }, { "nct_id": "NCT01694407", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Tenofovir (TFV) Alone Vaginal Tablet", "type": "DRUG" }, { "name": "Emtricitabine (FTC) Alone Vaginal Tablet", "type": "DRUG" }, { "name": "TFV and FTC Combined Vaginal Tablet", "type": "DRUG" }, { "name": "Placebo Vaginal Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CONRAD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 48, "start_date": "2013-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-04-03", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 2, "location_summary": "The Bronx, New York • Norfolk, Virginia", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01694407" }, { "nct_id": "NCT01330199", "title": "Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Females" ], "interventions": [ { "name": "Pharmacokinetic Sampling", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 49, "start_date": "2012-02", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330199" }, { "nct_id": "NCT07645287", "title": "A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-3242 Tablet", "type": "DRUG" }, { "name": "GS-3242 Injection", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Lenacapavir Injection", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2026-06-15", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-18T06:01:29.067Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645287" } ] }